# A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma

> **NCT05664243** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **In8bio Inc.** · enrollment: 4 (estimated)

## Conditions studied

- Glioblastoma

## Interventions

- **BIOLOGICAL:** Autologous genetically modified gamma-delta T cells
- **BIOLOGICAL:** Allogeneic genetically modified gamma-delta T cells

## Key facts

- **NCT ID:** NCT05664243
- **Lead sponsor:** In8bio Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-09-08
- **Primary completion:** 2025-12
- **Final completion:** 2025-12
- **Target enrollment:** 4 (ESTIMATED)
- **Last updated:** 2025-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05664243

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05664243, "A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05664243. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*